Review articleProbiotics: potential pharmaceutical applications
Introduction
Probiotics are defined as the viable microorganisms that exhibit a beneficial effect on the health of the host by improving its intestinal microbial balance. The term probiotics was first coined by Lilly and Stillwell in 1965 in reference to substances produced by protozoa, which stimulated the growth of other organisms. Interest in probiotics has been spurred by the growing abundance of modern disorders such as neoplasms, atherosclerosis, cardiac diseases, hypertension and HIV infection. Probiotic consumption is reported to exert a myriad of beneficial effects including: enhanced immune response, balancing of colonic microbiota, vaccine adjuvant effects, reduction of fecal enzymes implicated in cancer initiation, treatment of diarrhea associated with travel and antibiotic therapy, control of rotavirus and Clostridium difficile-induced colitis and prevention of ulcers related to Helicobacter pylori. Probiotics are also implicated in the reduction of serum cholesterol, the antagonism against food-borne pathogens and tooth decay organisms, the amelioration of lactose malabsorption symptoms as well as candidiasis and urinary tract infections (Saavedra, 2001). Promising probiotic strains include the members of genera Lactobacillus, Bifidobacterium, and Enterococcus. The representative species include Lactobacillus acidophilus, L. johnsonii, L. casei, L. gasseri, L. plantarum, L. rhamnosus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium infantis, Enterococcus faecalis and Enterococcus faecium (Fuller, 1991, Gordin and Gorbach, 1992). They have considerable potential for further inclusion in functional foods and health-related products. Even though these health claims are generally accepted by scientists and consumers, however the underlying molecular mechanisms remain controversial. An in depth investigation of the molecular basis of probiotic traits will give a vital reinforcement to the probiotic concept and is a pre-requisite for their rational development.
Section snippets
Properties and proposed mechanism of action
A group of requirements have been identified for a microorganism to be defined as an effective probiotic (Salminen et al., 1996). These include the ability to: (a) adhere to cells; (b) exclude or reduce pathogenic adherence; (c) persist and multiply; (d) produce acids, hydrogen peroxide, and bacteriocins antagonistic to pathogen growth; (e) be safe, noninvasive, noncarcinogenic and nonpathogenic; and (f) coaggregate to form a normal balanced flora.
Emerging evidences have revealed that
Expected therapeutic uses
The commercial interest in functional foods that contain probiotics, is paralleled by increasing study of their role in the digestive tract. To date, interest in probiotic containing foods has centered around three health propositions (a) improving general gut health, (b) improving body’s natural defenses, and (c) lowering blood cholesterol.
Recombinant probiotic — subalin
A new probiotic class based on recombinant strains of bacteria has been designed to produce predetermined therapeutic proteins. The biological properties of Bacillus subtilis 2335 strain were transformed by the plasmid encoding the synthesis of human interferon alpha-2. The recombinant strain was demonstrated to preserve the high antagonistic activity of the parent culture (biosporin) and to acquire marked antiviral properties due to interferon synthesis. Using this strain, Sorokulova et al.
Prebiotics
It is a well-established fact that resistance to pathogens and an immune stimulation can be achieved by probiotic therapy. However, it is important that these exogenous bacteria (i.e. probiotics) reach the large intestine in an intact and viable form. Upon ingestion, these probiotics are confronted by a number of physical and chemical barriers such as gastric and bile acids. As a result only a small proportion of the probiotic microorganisms are able to reach and establish themselves in the
Conclusions and future perspectives
The global market for functional foods is growing at a very fast rate and the probiotic products represent a potential growth area. Intense research efforts are under way to develop products into which probiotic organisms such as Lactobacillus and Bifidobacterium species are incorporated. The long term exploitation of probiotics would depend on scientifically proven clinical evidence of health benefit, of consumer expectation and of effective marketing strategies (Stanton et al., 2001).
One
References (58)
- et al.
Protective nutrients and bacterial colonization in the immature human gut
Adv. Pediatr.
(1999) - et al.
Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998
Am. J. Clin. Nutr.
(2000) - et al.
Probiotic activities of Lactobacillus casei rhamnosus: In vitro adherence to intestinal cells and antimicrobial properties
Res. Microbiol.
(2001) - et al.
Effect of bifidobacteria feeding on fecal flora and production of immunoglobulins in lactating mouse
Int. J. Food Microbiol.
(1999) Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin
J. Nutr.
(1999)Immunoprophylaxis of atopy: light at the end of the tunnel
Immunol. Today
(1994)- et al.
Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice
Life Sci.
(1998) - et al.
Antimutagenic properties of probiotic bacteria and of organic acids
Mutat. Res.
(1998) - et al.
Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium
Am. J. Clin. Nutr.
(2001) - et al.
Lactobacillus endocarditis caused by a probiotic organism
Clin. Microbiol. Infect.
(1999)
Probiotics: a novel approach in the management of food allergy
J. Allergy Clin. Immunol.
The use of probiotics in medical practice
Int. J. Antimicrob. Agents
Study of adhesion of Lactobacillus casei CRL 431 to ileal intestinal cells of mice
J. Food Prot.
The effect of probiotics on Clostridium difficile diarrhea
Am. J. Gastroenterol.
Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth
J. Nutr.
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
Lancet
Probiotics and infectious diarrhea
Am. J. Gastroenterol.
Clinical application of probiotic agents
Am. J. Clin. Nutr.
Probiotics and inflammatory bowel diseases
Am. J. Gastroenterol.
Evidence for hypocholesterolemic effect of Lactobacillus reuteri in hypercholesterolemic mice
J. Dairy Sci.
Proinflammatory cytokine and nitric oxide induction in murine macrophages by cell wall and cytoplasmic extracts of lactic acid bacteria
J. Food Prot.
Ingestion of yogurt containing Lactobacillus acidophilus and Bifidobacterium to potentiate immunoglobulin A responses to cholera toxin in mice
J. Dairy Sci.
Modulation of the antitumor effect of cyclophosphamide by the recombinant probiotic Subalin
Vopr. Onkol.
Probiotics in paediatric gastrointestinal disorders
Curr. Opin. Pediatr.
Successful modification of human intestinal microflora with oral administration of lactic acid bacteria
Bratisl. Lek. Listy.
A bit of culture for children: probiotics may improve health and fight diseases
J. Am. Med. Assoc.
Probiotics in human medicine
Gut
Oligosaccharides and glycoconjugates in bovine milk and colostrums
Br. J. Nutr.
Probiotics for humans
Cited by (283)
Tuning Expectations to Reality: Don't Expect Increased Gut Microbiota Diversity with Dietary Fiber
2023, Journal of NutritionDiversity, distribution and role of probiotics for human health: Current research and future challenges
2023, Biocatalysis and Agricultural BiotechnologyChronic kidney disease and gut microbiota
2023, HeliyonReview - Sporeforming probiotic bacteria: Characteristics, health benefits, and technological aspects for their applications in foods and beverages
2023, Trends in Food Science and TechnologyCharacterization of Pediococcus acidilactici FS2 isolated from Korean traditional fermented seafood and its blood cholesterol reduction effect in mice
2021, Journal of Functional FoodsCitation Excerpt :Similarly, oral administration of P. acidilactici J9 and L. plantarum PH04 as probiotics did not cause significant changes in body weight and organ weight in mice (Lee et al., 2020; Nguyen et al., 2007). Lactic acid bacteria inhibit harmful bacteria by producing organic acids (lactic, acetic, formic, propionic, and butyric acids), bacteriocins (nisin and pediocin), and other antibacterial peptides in the host's intestine (da Silva Sabo et al., 2015; Kaur et al., 2002). It also enhances nonspecific and specific immune responses (Perdigón et al., 2001).